<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583270</url>
  </required_header>
  <id_info>
    <org_study_id>CERN-biofuncarb second meal</org_study_id>
    <secondary_id>2101-08-0068</secondary_id>
    <nct_id>NCT01583270</nct_id>
  </id_info>
  <brief_title>Effect of Arabinoxylan and Rye Kernels on Second Meal Responses</brief_title>
  <official_title>Effect of Arabinoxylan and Rye Kernels on Second Meal Responses in Subjects With the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sedentary lifestyles and increasing obesity are main causes of the global increase in the&#xD;
      prevalence of the metabolic syndrome (Mets) and type 2 diabetic (T2DM). Diet quality,&#xD;
      particularly composition of carbohydrate play also a significant role. Barley, oat and rye&#xD;
      may in addition to reducing the acute post prandial glucose response also reduce glucose&#xD;
      response at a subsequent meal. Purified dietary fibre has been shown to reduce GI and affect&#xD;
      levels of satiety hormones. In contrast, our knowledge of the physiological effect of&#xD;
      arabinoxylan, which constitute a substantial part of dietary fibre in cereal products, is&#xD;
      limited in relation to second meal effects. The investigators also lack knowledge of the&#xD;
      second meal effect of arabinoxyan in combination with rye kernels.&#xD;
&#xD;
      Hypothesis: Porridge rich in arabinoxylan and/or whole rye kernels can increase the formation&#xD;
      of short chain fatty acids and improve the glycemic response.&#xD;
&#xD;
      The aim of the present study is to compare the effect of porridge test meals based on&#xD;
      purified arabinoxylan, rye kernels, a combination of arabinoxylan and rye kernels, and&#xD;
      semolina porridge as control on acute postprandial response as well as response at a&#xD;
      subsequent standardized meal. The study will be conducted in subjects with the metabolic&#xD;
      syndrome. The primary endpoint is glucose response. Secondary endpoints are the following&#xD;
      items: insulin, incretins, inflammatory markers, ghrelin, free fatty acids, metabolomics,&#xD;
      breath hydrogen and subjective satiety feeling.&#xD;
&#xD;
      This project will improve opportunities for identifying and designing foods with low GI that&#xD;
      is particularly suited to people who are at high risk of developing T2DM. The investigators&#xD;
      also expect to gain a greater understanding of the metabolic fingerprint, as seen after&#xD;
      ingestion of low-GI foods and thereby gain a molecular understanding of how low-GI foods&#xD;
      affect health by altering metabolic processes. This will give us a deeper insight into the&#xD;
      metabolic processes that are necessary for maintaining normal glucose homeostasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a cross-over design, 15 subjects with Mets will consume test meals containing four&#xD;
      different porridges in randomized order. Blood samples will be collected over 2 hours after&#xD;
      ingestion of test meals and 2 hours after ingestion of a standard second lunch meal served 4&#xD;
      hours after the test meals. The amount of porridge and the standard lunch are equivalent to&#xD;
      50 g available carbohydrate. Visual Analog Scale (VAS) will be used for determination of&#xD;
      subjective satiety feeling and measurements of breath hydrogen will be used as a marker for&#xD;
      colon fermentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose response after second meal</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma response after second meal</measure>
    <time_frame>2 hours</time_frame>
    <description>Plasma insulin, incretins, ghrelin, short chain fatty acids, freee fatty acids, inflammation markers, and metabolomics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma response after test meal</measure>
    <time_frame>2 hours</time_frame>
    <description>Plasma glucose, insulin, incretins, short chain fatty acids, free fatty acids, metabolomisc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath hydrogen after second meal</measure>
    <time_frame>2 hours</time_frame>
    <description>Breath hydrogen as marker for colon fermentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath hydrogen after testmeal</measure>
    <time_frame>2 hours</time_frame>
    <description>Breath hydrogen as marker for colen fermentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety feeling after second meal</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety feeling after test meal</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arabinoxylan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Porridge rich in arabinoxylan. 50 g available carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rye kernels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Porridge made from rye kernels. 50 g available carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arabinoxylan and rye kernels</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>semolina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Semoline porridge. 50 g available carbohydrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arabinoxylan</intervention_name>
    <description>Porridge rich in arabinoxylan</description>
    <arm_group_label>Arabinoxylan</arm_group_label>
    <other_name>Dietary fibre.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rye kernel</intervention_name>
    <description>Porridge made of rye kernels</description>
    <arm_group_label>rye kernels</arm_group_label>
    <other_name>Whole grain. Rye. Kernels.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arabinoxylan and rye kernels</intervention_name>
    <description>Porridgde made of rye kernels and arabinoxylan</description>
    <arm_group_label>arabinoxylan and rye kernels</arm_group_label>
    <other_name>dietary fibre. whole grain. rye kernels.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Semolina</intervention_name>
    <description>Semoline porridge. control meal.</description>
    <arm_group_label>semolina</arm_group_label>
    <other_name>Wheat.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Central obesity (Female &gt; 94 cm; Male &gt; 80 cm) with two of the following:&#xD;
&#xD;
          1. fasting triglyceride (&gt; 1,7 mmol/L),&#xD;
&#xD;
          2. HDL-cholesterol: (Female:&lt; 1,03 mmol/L; Male:&lt; 1,29 mmol/L),&#xD;
&#xD;
          3. blood pressure (≥ 130/85 mmHg) and&#xD;
&#xD;
          4. fasting plasma glucose (≥ 5,6 mmol/L)). Subjects who are in medical treatment with&#xD;
             lipid and blood pressure-lowering drugs can continue with their habitual treatment&#xD;
             provided that the treatment is stable throughout the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  fasting plasma glucose &gt; 7,0 mmol/l,&#xD;
&#xD;
          -  fasting plasma triglyceride &gt; 5,0 mmol/l,&#xD;
&#xD;
          -  blood pressure &gt; 160/100 mmHg ,&#xD;
&#xD;
          -  legal incapacity , endocrine, cardiovascular or kidney disease,&#xD;
&#xD;
          -  BMI &gt; 38kg/m2,&#xD;
&#xD;
          -  corticosteroid treatment,&#xD;
&#xD;
          -  alcohol or drug addiction and&#xD;
&#xD;
          -  pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjeld Hermansen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2012</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>AnneMarie Kruse</investigator_full_name>
    <investigator_title>Professor Kjeld Hermansen</investigator_title>
  </responsible_party>
  <keyword>Arabinxylan</keyword>
  <keyword>Rye kernels</keyword>
  <keyword>whole grain</keyword>
  <keyword>Dietary fibre</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Glycemic response</keyword>
  <keyword>Colon fermentation</keyword>
  <keyword>Second meal effekt</keyword>
  <keyword>Satiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

